CZT Cozart

RNS Number:6012C
Cozart PLC
22 August 2007

                           Cozart plc (the "Company")



                            Notification of Results





Abingdon, Oxfordshire, 22 August 2007 - Cozart plc, the medical diagnostics
company, will be announcing its preliminary results for the year ended 31 May
2007 on 6 September 2007.



Enquiries:

Cozart plc:
Tel: 01235 861 483
Chris Yates, Finance Director
www.cozartgroup.com

Financial Dynamics:
Tel:  020 7269 7242
Ben Atwell
Emma Thompson



Notes to Editors - Cozart plc



Cozart is a medical diagnostics company which develops, manufactures and sells
immunodiagnostic tests, predominantly those used for the detection of drugs of
abuse. Cozart's products include laboratory based testing kits for the detection
of drugs in a variety of biological samples and the Cozart(R) RapiScan and
Cozart DDS systems, portable devices used for the on-site testing of drugs of
abuse in saliva (oral fluid) samples. In July 2004 Cozart floated on London's
AIM (trading symbol: CZT).   Cozart has wholly owned subsidiaries in Spain
(Spinreact SA based near Barcelona); Sweden (HL Scandinavia and Medib
Scandinavian), Italy (Cozart Italia) and UK (Nemesis Scientific Limited).



Cozart supplies point of contact testing products, laboratory services and
forensic testing kits to the criminal justice (e.g. police forces, probation
services and prisons), medical (e.g. hospitals and drug dependency clinics) and
workplace markets (e.g. pre-employment, random and 'for cause' testing) both in
the UK and internationally.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NORDGGZRNMKGNZM

Grafico Azioni Cozart (LSE:CZT)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Cozart (LSE:CZT)
Storico
Da Giu 2023 a Giu 2024